Enhanced Selective Inhibitors of EGFR Exon 20 Insertion Mutants

This inventive concept improves upon the original patent by introducing novel methods, systems, and compositions for treating EGFR-mutated lung cancer, enhancing the efficacy and safety of selective inhibitors, and providing personalized treatment options.

The original patent disclosed a method for treating malignant lung tumors with EGFR exon 20 insertion mutations. However, the existing approach has limitations in terms of monitoring treatment response, identifying responsive patients, and ensuring optimal bioavailability and toxicity profiles of the inhibitors. This inventive concept addresses these limitations by introducing non-invasive diagnostic imaging techniques, personalized treatment systems, and optimized pharmaceutical compositions.

The new claims introduce several key advancements. Firstly, the method of claim 1 incorporates monitoring of treatment response using non-invasive diagnostic imaging techniques, enabling more accurate assessment of inhibitor efficacy. Secondly, the system of claim 2 provides personalized cancer treatment by analyzing genomic information and selecting corresponding selective inhibitors. Thirdly, the pharmaceutical composition of claim 3 enhances the bioavailability and reduces the toxicity of the inhibitors. Additionally, the method of claim 4 identifies responsive patients by detecting biomarkers associated with the inhibitor's efficacy, and the kit of claim 5 facilitates diagnosis of EGFR exon 20 insertion mutations.

The new claims introduce several novel and non-obvious features, including the use of non-invasive diagnostic imaging techniques for monitoring treatment response, the integration of genomic information analysis for personalized treatment, and the optimization of pharmaceutical compositions for enhanced bioavailability and reduced toxicity.

Alternative embodiments of the inventive concept could include the use of different non-invasive diagnostic imaging techniques, such as MRI or PET scans, or the integration of additional biomarkers for identifying responsive patients. Variations of the pharmaceutical composition could include different carrier molecules or formulations to further enhance the inhibitor's efficacy and safety.

The enhanced selective inhibitors of EGFR exon 20 insertion mutants have significant commercial potential in the oncology market, particularly in the treatment of non-small cell lung cancer. The personalized treatment approach and optimized pharmaceutical compositions could provide a competitive advantage in the market, and the diagnostic kit could generate additional revenue streams.